Your browser doesn't support javascript.
loading
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Schalck, Aislyn; Sakellariou-Thompson, Donastas; Forget, Marie-Andrée; Sei, Emi; Hughes, Tara G; Reuben, Alexandre; Bai, Shanshan; Hu, Min; Kumar, Tapsi; Hurd, Mark W; Katz, Matthew H G; Tzeng, Ching-Wei D; Pant, Shubham; Javle, Milind; Fogelman, David R; Maitra, Anirban; Haymaker, Cara L; Kim, Michael P; Navin, Nicholas E; Bernatchez, Chantale.
Afiliação
  • Schalck A; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sakellariou-Thompson D; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Forget MA; Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sei E; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hughes TG; Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Reuben A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bai S; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu M; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kumar T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hurd MW; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Katz MHG; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tzeng CD; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pant S; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Javle M; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fogelman DR; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maitra A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haymaker CL; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kim MP; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Navin NE; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bernatchez C; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
Cancer Discov ; 12(10): 2330-2349, 2022 10 05.
Article em En | MEDLINE | ID: mdl-35849783
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of knowledge on the tumor-infiltrating lymphocyte (TIL) landscape in PDAC. To generate a reference of T-cell subpopulations, we profiled 80,000 T cells from 57 PDAC samples, 22 uninvolved/normal samples, and cultured TIL using single-cell transcriptomic and T-cell receptor analysis. These data revealed 20 cell states and heterogeneous distributions of TIL populations. The CD8+ TIL contained a putative transitional GZMK+ population based on T-cell receptor clonotype sharing, and cell-state trajectory analysis showed similarity to a GZMB+PRF1+ cytotoxic and a CXCL13+ dysfunctional population. Statistical analysis suggested that certain TIL states, such as dysfunctional and inhibitory populations, often occurred together. Finally, analysis of cultured TIL revealed that high-frequency clones from effector populations were preferentially expanded. These data provide a framework for understanding the PDAC TIL landscape for future TIL use in immunotherapy for PDAC.

SIGNIFICANCE:

To improve the efficacy of immunotherapy in PDAC, there is a great need to understand the PDAC TIL landscape. This study represents a reference of PDAC TIL subpopulations and their relationships and provides a foundation upon which to base future immunotherapeutic efforts. This article is highlighted in the In This Issue feature, p. 2221.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article
...